TY  - JOUR
AU  - Bass, Ann D
AU  - Arroyo, Rafael
AU  - Boster, Aaron L
AU  - Boyko, Alexey N
AU  - Eichau, Sara
AU  - Ionete, Carolina
AU  - Limmroth, Volker
AU  - Navas, Carlos
AU  - Pelletier, Daniel
AU  - Pozzilli, Carlo
AU  - Ravenscroft, Jennifer
AU  - Sousa, Livia
AU  - Tintoré, Mar
AU  - Uitdehaag, Bernard M J
AU  - Baker, Darren P
AU  - Daizadeh, Nadia
AU  - Choudhry, Zia
AU  - Rog, David
AU  - CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ investigators
PY  - 2020
DO  - 10.1016/j.msard.2020.102717
UR  - http://hdl.handle.net/10668/17008
T2  - Multiple sclerosis and related disorders
AB  - Alemtuzumab significantly improved clinical and MRI outcomes vs. subcutaneous interferon beta-1a (SC IFNB-1a) in the CARE-MS trials (NCT00530348, NCT00548405), with sustained efficacy in 2 consecutive extensions (NCT00930553, NCT02255656 [TOPAZ])....
LA  - en
KW  - Age
KW  - Alemtuzumab
KW  - Efficacy
KW  - Long-term
KW  - Safety
KW  - Alemtuzumab
KW  - Antibodies, Monoclonal, Humanized
KW  - Child
KW  - Humans
KW  - Interferon beta-1a
KW  - Middle Aged
KW  - Multiple Sclerosis, Relapsing-Remitting
KW  - Treatment Outcome
TI  - Alemtuzumab outcomes by age: Post hoc analysis from the randomized CARE-MS studies over 8 years.
TY  - research article
VL  - 49
ER  -